105 related articles for article (PubMed ID: 24997317)
1. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.
D'Avolio A; Carcieri C; Cusato J; Simiele M; Calcagno A; Allegra S; Sciandra M; Trentini L; Di Perri G; Bonora S
J Antimicrob Chemother; 2014 Nov; 69(11):3061-6. PubMed ID: 24997317
[TBL] [Abstract][Full Text] [Related]
2. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study.
Fatiguso G; Allegra S; Calcagno A; Baietto L; Motta I; Favata F; Cusato J; Bonora S; Perri GD; D'Avolio A
Int J Pharm; 2016 Jan; 497(1-2):287-92. PubMed ID: 26642947
[TBL] [Abstract][Full Text] [Related]
3. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells.
D'Avolio A; Simiele M; Calcagno A; Siccardi M; Larovere G; Agati S; Baietto L; Cusato J; Tettoni M; Sciandra M; Trentini L; Di Perri G; Bonora S
J Antimicrob Chemother; 2013 Apr; 68(4):907-10. PubMed ID: 23221630
[TBL] [Abstract][Full Text] [Related]
4. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
[TBL] [Abstract][Full Text] [Related]
5. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).
Bonora S; Rusconi S; Calcagno A; Bracchi M; Viganò O; Cusato J; Lanzafame M; Trentalange A; Marinaro L; Siccardi M; D'Avolio A; Galli M; Di Perri G
J Antimicrob Chemother; 2015 Nov; 70(11):3096-9. PubMed ID: 26174719
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.
Schipani A; Siccardi M; D'Avolio A; Baietto L; Simiele M; Bonora S; Rodríguez Novoa S; Cuenca L; Soriano V; Chierakul N; Saguenwong N; Chuchuttaworn C; Hoskins JM; Dvorak AM; McLeod HL; Davies G; Khoo S; Back DJ; Di Perri G; Owen A
Antimicrob Agents Chemother; 2010 Dec; 54(12):5242-50. PubMed ID: 20921307
[TBL] [Abstract][Full Text] [Related]
7. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
Focà E; Calcagno A; Bonito A; Simiele M; Domenighini E; D'Avolio A; Quiros Roldan E; Trentini L; Casari S; Di Perri G; Castelli F; Bonora S
J Antimicrob Chemother; 2017 Nov; 72(11):3163-3166. PubMed ID: 28961777
[TBL] [Abstract][Full Text] [Related]
8. A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
Kile DA; MaWhinney S; Aquilante CL; Rower JE; Castillo-Mancilla JR; Anderson PL
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1227-34. PubMed ID: 22394315
[TBL] [Abstract][Full Text] [Related]
9. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
[TBL] [Abstract][Full Text] [Related]
10. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
11. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
[TBL] [Abstract][Full Text] [Related]
12. Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study.
Nishijima T; Tsuchiya K; Tanaka N; Joya A; Hamada Y; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
J Antimicrob Chemother; 2014 Dec; 69(12):3320-8. PubMed ID: 25151207
[TBL] [Abstract][Full Text] [Related]
13. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
Siccardi M; D'Avolio A; Baietto L; Gibbons S; Sciandra M; Colucci D; Bonora S; Khoo S; Back DJ; Di Perri G; Owen A
Clin Infect Dis; 2008 Nov; 47(9):1222-5. PubMed ID: 18831695
[TBL] [Abstract][Full Text] [Related]
14. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.
Calcagno A; Baietto L; Pagani N; Simiele M; Audagnotto S; D'Avolio A; De Rosa FG; Di Perri G; Bonora S
Pharmacogenomics; 2014 Jul; 15(10):1281-6. PubMed ID: 25155930
[TBL] [Abstract][Full Text] [Related]
16. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
[TBL] [Abstract][Full Text] [Related]
17. Low atazanavir concentrations in cerebrospinal fluid.
Best BM; Letendre SL; Brigid E; Clifford DB; Collier AC; Gelman BB; McArthur JC; McCutchan JA; Simpson DM; Ellis R; Capparelli EV; Grant I;
AIDS; 2009 Jan; 23(1):83-7. PubMed ID: 19050389
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Boffito M; Jackson A; Amara A; Back D; Khoo S; Higgs C; Seymour N; Gazzard B; Moyle G
Antimicrob Agents Chemother; 2011 Sep; 55(9):4218-23. PubMed ID: 21709075
[TBL] [Abstract][Full Text] [Related]
19. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
20. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
